13.87 USD
+0.26 (+1.91%)
Last: Jan 30, 2026, 03:52 PM
Overall COEP gets a fundamental rating of 0 out of 10. We evaluated COEP against 525 industry peers in the Biotechnology industry. COEP may be in some trouble as it scores bad on both profitability and health. COEP is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- In the past 5 years COEP always reported negative net income.
- COEP had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
- The profitability ratios for COEP are negative, so there is not much use analyzing them.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- COEP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- COEP has more shares outstanding than it did 1 year ago.
- The debt/assets ratio for COEP has been reduced compared to a year ago.
2.2 Solvency
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | N/A |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | N/A | ||
| Quick Ratio | N/A |
3. Growth
3.1 Past
EPS 1Y (TTM)N/A
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- No dividends for COEP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
COEPTIS THERAPEUTICS HOLDING / COEP FAQ
What is the ChartMill fundamental rating of COEPTIS THERAPEUTICS HOLDING (COEP) stock?
ChartMill assigns a fundamental rating of 0 / 10 to COEP.
What is the valuation status of COEPTIS THERAPEUTICS HOLDING (COEP) stock?
ChartMill assigns a valuation rating of 0 / 10 to COEPTIS THERAPEUTICS HOLDING (COEP). This can be considered as Overvalued.
What is the profitability of COEP stock?
COEPTIS THERAPEUTICS HOLDING (COEP) has a profitability rating of 0 / 10.
How financially healthy is COEPTIS THERAPEUTICS HOLDING?
The financial health rating of COEPTIS THERAPEUTICS HOLDING (COEP) is 0 / 10.